Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues

Table 2 Risk scoring system for hepatocellular carcinoma in chronic hepatitis B

CU-HCC score[76]		GAG-HCC score[75]		REACH-B score[77]
Variable	Points	Variable	Points	Variable	Points
Age		Age		Age
> 50 yr	3	Per year	1	Per 5 years over 30	1
Albumin		Gender		Gender
< 3.5 g/dL	20	Male	16	Male	2
Bilirubin		BCP mutations		ALT (IU/L)
> 1.1 mg/dL	1.5	Present	19	15-44	1
Cirrhosis		Cirrhosis		≥ 45	2
Presence	15	Presence	30	HBeAg (+)	2
HBV-DNA		HBV-DNA		HBV-DNA
4-6 log10	1	Per log10	3	< 4log10	0
> 6 log10	4			4 - < 5log10	3
				5 - < 6log10	5
				≥ 6log10	4
Risk category		Risk category		Risk category
Low	< 5	Low	< 101	A 17 point risk scale
Intermediate	5-20	High	≥ 101
High	> 20

CU-HCC: Chinese University-Hepatocellular Carcinoma Score; GAG-HCC: Guide with Age, Gender, HBV-DNA, Core Promoter Mutations and Cirrhosis; REACH-B: Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B; BCP: Basic core promoter; ALT: Alanine transaminase.